XML 141 R132.htm IDEA: XBRL DOCUMENT v3.25.2
Share-based compensation plan - Phantom shares plan ("PS") and Restricted Shares (Details)
 6 Months Ended 12 Months Ended
Jun. 30, 2025
BRL (R$)
shares
R$ / shares
shares
Dec. 31, 2024
BRL (R$)
shares
Dec. 31, 2023
BRL (R$)
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Share-based compensation plans | R$ R$ 331,590,000 R$ 361,974,000  
PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Number of other equity instruments outstanding in share-based payment arrangement 10,938,121 10,096,497  
Shares granted 3,965,114    
Cancelled 444,148    
Exercised (1) 2,679,342    
Available for completion 1,561,676    
Restricted stock, year one 51,415    
Restricted stock, year two 2,899,312    
Restricted stock, year three 2,694,459    
Restricted stock, year four 3,731,259    
Decrease Provision Share Based Payment Cancelled | R$ R$ (11,324,000) R$ (23,470,000)  
Share-based compensation plans | R$ 331,590,000 361,974,000 R$ 268,489,000
Increase Provision Share Based Payment | R$ 78,485,000 196,956,000  
Decrease Provision Share Based Payment | R$ R$ (97,545,000) R$ (80,001,000)  
Phantom Share Units Psus      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Phantom Share Units Psus | R$ / shares R$ 58.91    
Restricted share units      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Number of other equity instruments outstanding in share-based payment arrangement 3,076,116 2,980,111  
Shares granted 563,980    
Exercised (1) 467,975    
Restricted stock, year two 504,946    
Restricted stock, year three 431,331    
Restricted stock, year four 230,773    
Share-based compensation plans | R$ R$ 57,620,000 R$ 60,226,000 R$ 26,744,000
Increase Provision Share Based Payment | R$ 22,520,000 81,276,000  
Decrease Provision Share Based Payment | R$ R$ (25,126,000) (47,794,000)  
Grant Year 2020 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 38.50  
Number of other equity instruments outstanding in share-based payment arrangement 33,384  
Shares granted 1,083    
Exercised (1) 34,467    
Available for completion    
Grant Year 2021 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 62.25  
Number of other equity instruments outstanding in share-based payment arrangement 37,461 874,480  
Shares granted 28,375    
Cancelled 13,046    
Exercised (1) 852,348    
Available for completion 37,461    
Restricted stock, year one    
Grant Year 2022 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 57.48  
Number of other equity instruments outstanding in share-based payment arrangement 1,911,872 3,461,437  
Shares granted 112,251    
Cancelled 106,324    
Exercised (1) 1,555,492    
Available for completion 1,524,215    
Restricted stock, year one 50,429    
Restricted stock, year two 313,255    
Restricted stock, year three 23,973    
Grant Year 2022 | Restricted share units      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 53.81  
Number of other equity instruments outstanding in share-based payment arrangement 115,800  
Shares granted 3,758    
Exercised (1) 119,558    
Grant Year 2023 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 48.84  
Number of other equity instruments outstanding in share-based payment arrangement 2,860,123 3,052,179  
Shares granted 98,965    
Cancelled 164,360    
Exercised (1) 126,661    
Restricted stock, year one 986    
Restricted stock, year two 2,583,070    
Restricted stock, year three 276,067    
Grant Year 2023 | Restricted share units      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 51.41  
Number of other equity instruments outstanding in share-based payment arrangement 396,016 383,568  
Shares granted 12,448    
Restricted stock, year two 277,249    
Restricted stock, year three 118,767    
Grant Year 2024 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 56.53  
Number of other equity instruments outstanding in share-based payment arrangement 2,584,161 2,675,017  
Shares granted 86,665    
Cancelled 113,617    
Exercised (1) 63,904    
Restricted stock, year two 2,987    
Restricted stock, year three 2,394,419    
Restricted stock, year four 186,755    
Grant Year 2024 | Restricted share units      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 55.77  
Number of other equity instruments outstanding in share-based payment arrangement 2,212,835 2,480,743  
Shares granted 80,509    
Exercised (1) 348,417    
Restricted stock, year two 227,697    
Restricted stock, year three 312,564    
Grant Year 2025 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 60.53  
Number of other equity instruments outstanding in share-based payment arrangement 3,544,504  
Shares granted 3,637,775    
Cancelled 46,801    
Exercised (1) 46,470    
Restricted stock, year four 3,544,504    
Grant Year 2025 | Restricted share units      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 61.39  
Number of other equity instruments outstanding in share-based payment arrangement 467,265  
Shares granted 467,265    
Restricted stock, year two    
Restricted stock, year three    
Restricted stock, year four 230,773